Leading developer of novel medical devices selects clinivation WorldView® as their enterprise solution for on-demand global regulatory intelligence.
Natick, MA, November 19, 2008 – clinivation, Inc. announced today that CeloNova BioSciences Inc. has selected the clinivation WorldView® enterprise solution for On-Demand Global Regulatory Intelligence.
“CeloNova is a one of the world’s foremost developers of novel medical devices, and we are pleased that they have chosen clinivation WorldView® for comprehensive, authoritative, and up-to-date global regulatory intelligence,” said Richard Morroney, R.A.C., C.Q.A., clinivation’s Vice President of Quality and Regulatory Solutions.
About clinivation WorldView® On-Demand Global Regulatory Intelligence
Clinivation WorldView® is the medical device and diagnostic industry’s most comprehensive, authoritative, and up-to-date enterprise solution for On-Demand Global Regulatory Intelligence. Providing clear, step-by-step market clearance regulations, processes, and guidance for >99% of the world markets, only clinivation WorldView® delivers tried-and-true intelligence from certified, practicing professionals with real-world experience.
About CeloNova BioSciences
Headquartered in Newnan, Georgia, CeloNova BioSciences creates safe and effective solutions for complex technological and biomedical problems. CeloNova BioSciences develops novel medical devices that are then enhanced by one of the company’s proprietary materials, Polyzene®-F. Polyzene®-F is highly lubricious, anti-thrombotic, anti-inflammatory, and bacterial-resistant, making it an ideal surface treatment for implanted medical devices. CeloNova’s current products include Embozene™ Color-Advanced Microspheres and the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F. For more information, please visit www.celonova.com.